Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Jefferies Cuts Price Target on Marinus Pharma (MRNS) to $13 Following 4Q
March 8, 2016 8:34 AM ESTJefferies maintained a Buy rating on Marinus Pharmaceuticals (NASDAQ: MRNS), and cut the price target to $13.00 (from $14.00), following the company's 4Q. Total operating expenses for Q4 were $7.5M consisting of $6.1M of R&D and $1.4M G&A expense. MRNS is set to announce... More
Marinus Pharma (MRNS) Reports Q4 Loss of $0.45
March 7, 2016 7:35 AM ESTMarinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.45), versus ($0.26) reported last year.
For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.
... More